A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2015
• Main ID: NCT01279967
• Date of registration: 19/01/2011
• Prospective Registration: No
• Primary sponsor: Barts & The London NHS Trust
• Public title: A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma ADAM
• Scientific title: A Randomized Stratified Multicentre Phase II Clinical Trial of Single Agent ADI-PEG 20TM (Pegylated Arginine Deiminase) in Patients With Malignant Pleural Mesothelioma
• Date of first enrolment: January 2011
• Target sample size: 70
• Recruitment status: Active, not recruiting
• URL: http://clinicaltrials.gov/show/NCT01279967
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
• Phase: Phase 2

Countries of recruitment

United Kingdom

Contacts

• Name: Peter Szlosarek
• Affiliation: Barts and the London NHS

Key inclusion & exclusion criteria

Inclusion Criteria:

1. Males and Females aged 18 years and older. (There is no upper age limit)

2. Histopathological evidence of ASS-negative MPM. All biopsies will be reviewed for ASS
expression using immunohistochemistry. Central lab confirmation is required before
randomization

3. Performance status ECOG = 1. Life expectancy should be greater than 3 months

4. Chemo-naive patients OR, Patients who have been previously treated with
platinum-based combination chemotherapy with progressive disease at entry. In the
event of a baseline diagnostic ASS-positive test, a repeat biopsy confirming loss of
ASS expression will be required post platinum-based combination chemotherapy, with at
least a 4 week interval from the last treatment episode.

5. CT evaluable disease by modified RECIST criteria

6. Adequate bone marrow function, or supported through treatment:

- Haemoglobin 10g/dl or greater.

- White cell count 2 x 109/L or greater, neutrophil count 1.5 x 109/L or greater

- Platelets 75 x 109 /L or greater.

7. Adequate hepatic function (AST and ALT < 3 x upper limit of normal; bilirubin < 1.5 x
upper limit of normal)

8. Creatinine clearance >30ml/min

9. Able to give written informed consent to participate

Exclusion Criteria:

1. Participation in another clinical trial using an investigational agent

2. Patients with surgically resectable disease

3. Recurrent pleural effusion (not pleurodesed)

4. Receipt of extensive radiation (hemi-thorax) therapy within 6 weeks before
enrollment. Radiation to chest port sites following thoracotomy is permitted

5. A history of prior malignant tumour, unless the patient has been without evidence of
disease for at least three years, or the tumour was a non-melanoma skin tumour or
in-situ cervix carcinoma

6. Symptomatic or known brain or leptomeningeal metastases

7. Uncontrolled or severe cardiovascular disease including myocardial infarction within
6 months of enrollment

8. New York Heart Association (NYHA) Class III or IV heart failure (Attachment 10, NYHA
Classification of Cardiac Disease), uncontrolled angina, clinically significant
pericardial disease, or cardiac amyloidosis

9. Serious medical (e.g. uncontrolled diabetes, hepatic disease, infection, uncontrolled
gout) or psychiatric illness likely to interfere with participation in this clinical
study

10. History of seizures

11. Patients of child-bearing age must not become pregnant. Females of childbearing
potential must have a negative pregnancy test within 7 days prior to being registered
for protocol therapy. All patients enrolled on the study must agree to use acceptable
birth control measures whilst on the study; using both barrier and hormonal methods.
Patients that are surgically sterile are also eligible to participate in this study

12. Females must not be breastfeeding

13. Prior exposure to ADI-PEG 20

14. Preplanned surgery or procedures that would interfere with the study protocol

15. Allergy to pegylated products

16. Exposure to another investigational drug within 4 weeks prior to start of study
treatment



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Malignant Pleural Mesothelioma

Intervention(s)

Drug: ADI-PEG 20

Primary Outcome(s)

progression-free survival [Time Frame: 18 months]

Secondary Outcome(s)

time to progression [Time Frame: 18 months]

overall survival [Time Frame: 18 months]

safety (adverse events) [Time Frame: 18 months]

response rate [Time Frame: 18 months]

Secondary ID(s)

2006-004592-35

6837

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Cancer Research UK

UK: Barts Center for Experimental Cancer Medicine (CECM) for Trial Coordination